Following the conference call regarding Pacific Biosciences' new sequencing platform, the Sequel System, Piper Jaffray analyst William Quirk said that the call highlighted throughput improvements, a lower price point for the system compared to its predecessor and larger SMRT Cell consumables that will carry a higher price. The higher price for the SMRT cells will likely lead to higher consumable gross margins, the analyst said. Quirk is now forecasting 81 Sequel installs for 2016, compared to the firm's original 56 RS II placement estimate. The analyst keeps a Neutral rating on Pacific Bio shares.